Single Injection Delivery Systems

Exclusively Licensed

Emulsion-based and micromolded ("MM") or three dimensional printed ("3DP") polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been developed. Formulations are preferably formed of biocompatible, biodegradable polymers. Discrete regions encapsulating antigen, alone or in combination with other antigens, adjuvants, stabilizers, and release modifiers, are present in the formulations. Antigen is preferably present in excipient at the time of administration, or on the surface of the formulation, for immediate release, and incorporated within the formulation for release at ten to 45 days after initial release of antigen, optionally at ten to 90 day intervals for release of antigen in one or more additional time periods. Antigen may be stabilized through the use of stabilizing agents such as trehalose glass. In a preferred embodiment for immunization against polio, antigen is released at the time of administration, and two, four and six months thereafter.

Researchers

Robert Langer / Kevin McHugh / James Norman / Stephany Tzeng / Thanh Nguyen / William Gates / Boris Nikolic / Phillip Eckhoff / Lowell Wood / Ana Jaklenec / No Inventor

Departments: Office of the Institute Professors, David H Koch Institute for Integrative Cancer Res
Technology Areas: Drug Delivery: Microparticles & Nanoparticles / Therapeutics: Proteins & Antibodies, Vaccines
Impact Areas: Healthy Living

  • micromolded or 3-d printed pulsatile release vaccine formulations
    United States of America | Published application
  • micromolded or 3-d printed pulsatile release vaccine formulations
    Australia | Granted | 2,014,364,930
  • single injection delivery systems
    European Patent Convention | Granted | 3,082,852
  • micromolded or 3-d printed pulsatile release vaccine formulations
    United States of America | Granted | 10,300,136
  • micromolded or 3-d printed pulsatile release vaccine formulations
    Canada | Published application
  • micromolded or 3-d printed pulsatile release vaccine formulations
    United States of America | Granted | 10,960,073
  • micromolded or 3-d printed pulsatile release vaccine formulations
    Japan | Published application
  • micromolded or 3-d printed pulsatile release vaccine formulations
    United States of America | Pending
  • single injection delivery systems
    Switzerland | Granted | 3,082,852
  • single injection delivery systems
    Liechtenstein | Granted | 3,082,852
  • single injection delivery systems
    Germany | Granted | 3,082,852
  • single injection delivery systems
    France | Granted | 3,082,852
  • single injection delivery systems
    United Kingdom | Granted | 3,082,852
  • single injection delivery systems
    Ireland | Granted | 3,082,852
  • micromolded or 3-d printed pulsatile release vaccine formulations
    European Patent Convention | Published application
  • micromolded or 3-d printed pulsatile release vaccine formulations
    Japan | Published application
  • single injection delivery systems
    Belgium | Granted | 3,082,852
  • micromolded or 3-d printed pulsatile release vaccine formulations
    United States of America | Granted | 11,975,069

License this technology

Interested in this technology? Connect with our experienced licensing team to initiate the process.

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.

More Technologies